What are the pros and cons of bispecific antibodies for multiple myeloma?
Multiple Myeloma Hub
Advancements in Bi-Specific Antibodies for Multiple Myeloma
A comprehensive overview of the effectiveness and challenges of bi-specific antibodies targeting agents like BCMA, Tolketamab, and Sivostamab, showcasing promising results comparable to CAR-T therapy. The chapter delves into implications, patient response rates, safety profiles, challenges in drug delivery, and direct comparisons with CAR-T therapies.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
